Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Clementia Pharmaceuticals Inc.
Montreal, Quebec, Canada
- Ownership
- Private
- Development stage
- Other
01
Overview
Clementia was developing palovarotene, a novel RARγ agonist, for the treatment of FOP. The company was preparing for a 2019 NDA submission to the FDA. The Phase 3 MOVE Trial was evaluating an additional dosing regimen of palovarotene. Palovarotene was also in a Phase 2 trial (MO-Ped Trial) for multiple osteochondromas. The company was acquired by Ipsen in April 2019.
- Therapeutic areas
- OphthalmologyRare Diseases
- Modalities
- Small moleculesRARγ agonists
- Industry
- Biotech
Beyond the preview
Go deeper on Clementia Pharmaceuticals Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Clementia Pharmaceuticals Inc..